Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 10/20 | 0.55 |
| ▸ | DGKA | P23743 | 4/20 | 0.41 |
| ▸ | DGKZ | Q13574 | 4/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | GPR6 | P46095 | 1/20 | 0.40 |
| ▸ | DGKI | O75912 | 1/20 | 0.37 |
| ▸ | DGKG | P49619 | 1/20 | 0.37 |
| ▸ | DGKK | Q5KSL6 | 1/20 | 0.37 |
| ▸ | DGKB | Q9Y6T7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133747 | 1.00 | SCD (0.55) | SCDDGKADGKZCHRM4GPR6 | |
| SCHEMBL23526838 | 0.92 | SCD (0.45) | SCDDGKADGKZCHRM4GPR6 | |
| SCHEMBL31133715 | 0.92 | SCD (0.45) | SCDDGKADGKZCHRM4GPR6 | |
| SCHEMBL31133806 | 0.90 | SCD (0.53) | SCDDGKADGKZ | |
| SCHEMBL23526978 | 0.90 | SCD (0.53) | SCDDGKADGKZ | |
| SCHEMBL23526837 | 0.89 | SCD (0.44) | SCDDGKADGKZGPR6DGKI | |
| SCHEMBL31133649 | 0.89 | SCD (0.44) | SCDDGKADGKZGPR6DGKI | |
| SCHEMBL23527042 | 0.89 | DGKA (0.45) | SCDDGKADGKZCHRM4GPR6 | |
| SCHEMBL31133628 | 0.89 | DGKA (0.45) | SCDDGKADGKZCHRM4GPR6 | |
| SCHEMBL23527107 | 0.87 | GPR6 (0.43) | SCDDGKADGKZCHRM4GPR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081523-B1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-25 | — | — | EP | claimed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | claimed |
| WO-2021133750-A1 | SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-01 | — | — | WO | claimed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | claimed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188845-A1 | SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKA, DGKZ, DGKK | SCD 2447/4885DGKA 1/4885DGKZ 2/4885 |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | SCD 2447/4885DGKA 1/4885DGKZ 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.